Clinical Trials
10 trialsNCT03082534 2026-01-28
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
University of California, San Diego
Phase 2 Completed
NCT00545545 2025-03-19
Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma
HiberCell, Inc.
Phase 1/2 Completed
NCT01864772 2022-08-19
ELANFIT
Groupe Oncologie Radiotherapie Tete et Cou
Phase 2 Completed
NCT02124707 2020-08-12
Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT02350712 2018-09-11
Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer
Daiichi Sankyo
Phase 1 Completed
NCT01252628 2018-05-16
Phase 1 and 2 Study of PX-866 and Cetuximab
Seagen Inc.
Phase 1/2 Completed
NCT01040832 2017-01-30
EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
EMD Serono
Phase 2 Completed
NCT01133665 2014-11-24
Cetuximab and Lenalidomide in Head and Neck
University of Chicago
Phase 2 Completed
NCT00705016 2014-04-30
ADVANTAGE
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed
NCT00095199 2012-10-15
Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 3 Completed